Introduction
============

Hepatitis B is a viral infection and a common cause of liver disease and cancer ([@B1],[@B2]). Hepatitis B vaccine has become available since 1982. Nevertheless, chronic HBV infection has remained one of the major global problems for public health and a main cause of deaths from cirrhosis and liver malignancy in the world ([@B3]--[@B5]). Although the spread of the virus infection in developed countries is relatively low, it is still prevalent in eastern and Southeast Asia ([@B6]--[@B8]).

The hepatitis B immune coverage increased from the beginning of 2000 with the support of the global union for vaccination and immunization ([@B9]). The national vaccination program for hepatitis B virus for all newborns and high-risk groups began in 1993 in Iran. Since then, all newborn babies have been covered by the vaccination program and receive the vaccine in three stages at regular intervals: at birth, 1.5 months after birth, and 9 months after birth. Thus, the epidemiological pattern of the prevalence of hepatitis B virus has changed over time in Iran, and a reduction has been reported in both the acute and chronic infection of the virus ([@B10]).

Iran is a medium-risk country with a prevalence of 2-7% and nearly 2 million adults with chronic infection. In another meta-analysis study ([@B11]), the prevalence of hepatitis B virus infection in the Iranian population was 2.2%. The highest prevalence of the virus was reported in Golestan province with 8.9% while the lowest in Kermanshah province with 0.7%. The prevalence of the virus was 2.9% before 2010, while after 2010 the prevalence dropped to 1.3%.

In clinical and epidemiological studies, to investigate the association between a binary exposure and response, the nature of these types of studies can often lead to misclassification due to the low accuracy of diagnostic tests. Because of the close association between the accuracy of the test and its sensitivity as well as specificity ([@B12]), misclassification is defined as a function of sensitivity and specificity for exposure and response.

One of the most important reasons for misclassification is the lack of a gold standard. Thus, by changing the definitions of classification, misclassification occurs. When clinical and laboratory data are available, this issue can be mitigated. Thus, clinical researchers can reduce the classification error according to the data. On the other hand, when data is not available, statistical techniques can be used. One of these techniques is the Bayesian method ([@B13]).

In a study that is prone to misclassification for both exposure and response; non-differential response correction can be matched by three models using the hierarchical Bayesian approach. Since the present study is a public vaccination and has been proceeded for a few decades, vaccination information may have a recall bias, and HBsAg marker can be associated with a slight error. Consequently, misclassification and unreported cases affect HBV sensitivity and Odds Ratio.

We applied Bayesian adjustment to obtain the real effect of the vaccination on hepatitis B virus and to estimate the validity as well as accuracy of the intensity of effect despite misclassification error and underreporting cases.

Methods
=======

**Source and study population**

This was a case control study in which both cases and controls were prone to misclassifications. Cases include those suspect to have hepatitis B virus referring to the gastroenterology and liver disease research center at Shahid Beheshti University of Medical Sciences by its vice chancellor in health affair. The control group included those who underwent a fatty liver test at Taleghani hospital laboratory and they were not suspect to carry hepatitis B virus.

**Modeling**

Exposure variable of the present study was being up to date in 3 times of communal vaccination and response variable was hepatitis B virus infection. Correction of exposure and response values was performed based on the assumption of exposure and response misclassification in accordance with the exposure misclassification approaches of Gustafson (14) and Luta et al. (15) via three models. These three models include exposure model (equation 1), measurement model (equation 2), and response model (equation 3), adjusted for appropriate covariates (in related studies (16--19), risk factors associated with HBV were selected) as follows:

$\mathit{logit}\left\{ {P\left\{ {\mathit{UTD} = 1} \right\}} \right\} = \alpha_{0} + \alpha_{1}\mathit{Age} + \alpha_{2}\mathit{Ethnicity} + \alpha_{3}\mathit{Surgury} + \alpha_{4}\mathit{Cupping}$

\(1\)

$p\left( \mathit{case}^{*} \right) = r\left( \mathit{SN} \right) + \left( {1 - r} \right)\left( {1 - \mathit{SP}} \right)$

\(2\)

$\mathit{logit}\left\{ {r = P\left\{ {\mathit{Case} = 1} \right\}} \right\} = \beta_{0} + \beta_{1}\mathit{UTD} + \beta_{2}\mathit{Age} + \beta_{3}\mathit{Ethnicity} + \beta_{4}\mathit{Surgury} + \beta_{5}\mathit{Cupping}$

\(3\)

**Priors/Validation data**

In order to implement the analysis in the Bayesian framework, it is necessary to specify the distribution of the parameters and the prior probabilities. In the exposure and response models, we used independent informative normal priors for the intercepts, covariates, as well as the up-to-dateness in the hepatitis B vaccine. Also, for the sensitivity (SN) and specificity (SP) in the measurement model, as prior distributions, it is required to calculate the number of reported cases and non-cases. We let A represent a true positive, B a false positive, C a true negative, and D a false negative. Also, E and F represent the number of unreported cases and controls in the remaining population, respectively. The values of the sensitivity priors changed subsequently with varying several degrees of underreporting, though the specificity remained almost perfect. Thus, for sensitivity and specificity, we used beta distribution with appropriate parameters as follows: for sensitivity, beta (A, C + E); and for specificity, beta (D + F, B). Precision estimates are provided as 95% confidence intervals and 95% credible limit ratios to facilitate comparisons.

**Bayesian framework**

In order to correct the values of exposure and response, we first consider correction of exposure values by the exposure model. The imperfect response values are also corrected using the beta distribution for sensitivity and specificity in the measurement model. Since the Bayesian inference of the posterior equation in logistic models (equations 1 and 3) will be in a complex form and create multi-dimensional density functions (20), the inferences were performed via Morkov Chain Monte Carlo simulation and Gibbs sampling algorithm.

**Resampling**

The present study population reflects the situation of Iran on a small scale (0.01% of the total Iranian population). Indeed, Iran is in the middle risk zone with a prevalence of about 2%. The prevalence of HBV infection was estimated to be 2.14 and 2.7 in the review studies by Alavian et al. ([@B21]) and Porolajal et al. ([@B22]), respectively. Therefore, assuming a study population of 8000, a sample of 300 was taken from the 3000 available data. Then, in order to determine the impact of unreported cases on sensitivity and subsequently the odds ratio, we changed the unreported cases to 0, 5, 50 and 500. For more accurate investigation of the pattern of changes in OR and misclassification rate and also to avoid random occurrences, the results were interpreted based on three-time resampling. Thus, at each step of the simulation, using 1000 Gibbs iterations and excluding 50% of the initial observations for burn-in, the correct state of vaccination and imperfect measure of HBV were imputed from the exposure and measurement model and regressed in the outcome model to form a posterior distribution of the estimates of the corrected odds ratios. Empirically, only simulations that improve the likelihood were retained to estimate the posterior distribution. The analysis was performed using R, version 3.5.1.

Results
=======

**Demographic changes of available data in the present study**

The frequency distribution of the 2000 reported cases and 1000 reported controls is reported in [Table 1](#T1){ref-type="table"}. Overall, 79% of the population were not up-to-date on their vaccination (n=2364), of whom 72% were cases (n=1694). Also, about half of the population was female (50%), mostly over 30 years (79%) and were married (86%). Compared to the control, most cases were from other ethnicities (65% vs. 50%), non-cupping (82% vs. 64%), and non-surgical (52% vs. 42%). Nevertheless, there was no significant difference for the incidence of smoking (18% vs. 13%) and alcohol use (5% vs. 4%).

###### 

Demographic changes of characteristics of the study and comparison of reported potential cases to controls

  Characteristic   Total No.   Total %   Case No.   Case %   Control No.   Control %
  ---------------- ----------- --------- ---------- -------- ------------- -----------
  Sex              3000                  2000                1000          
  Man              1515        50.5      1056       52.8     459           45.9
  Woman            1485        49.5      944        47.2     541           54.1
  Age              3000                  2000                1000          
  \<=30            642         21.4      588        29.4     54            5.4
  \>30             2358        78.6      1412       70.6     946           94.6
  Marriage         3000                  2000                1000          
  Not Married      416         13.9      299        15.0     117           11.7
  Married          2584        86.1      1701       85.1     883           88.3
  Education        3000                  2000                1000          
  Illiterate       404         13.5      374        18.7     30            3.0
  Not Illiterate   2596        86.5      1626       81.3     970           97.0
  Ethnicity        3000                  2000                1000          
  Fars             1187        39.6      692        34.6     495           49.5
  Others           1813        60.4      1308       65.4     505           50.5
  Cupping          3000                  2000                1000          
  Yes              710         23.7      351        17.6     359           35.9
  No               2290        76.3      1649       82.5     641           64.1
  Tattooing        3000                  2000                1000          
  Yes              341         11.4      167        8.4      174           17.4
  No               2659        88.6      1833       91.7     826           82.6
  Periodontal      3000                  2000                1000          
  Yes              1774        59.1      1534       76.7     240           24.0
  No               1226        40.9      466        23.3     760           76.0
  Sexuality        3000                  2000                1000          
  Yes              23          0.8       17         0.9      6             0.6
  No               2977        99.2      1983       99.2     994           99.4
  Shaving          3000                  2000                1000          
  Yes              386         12.9      330        16.5     56            5.6
  No               2614        87.1      1670       83.5     944           94.4
  Bloodslashing    3000                  2000                1000          
  Yes              114         3.8       56         2.8      58            5.8
  No               2886        96.2      1944       97.2     942           94.2
  HBsAg            3000                  2000                1000          
  Positive         2000        66.7      2000       100.0    0             0.0
  Negative         1000        33.3      0          0.0      1000          100.0
  HBsAb            3000                  2000                1000          
  Positive         366         12.2      5          0.3      361           36.1
  Negative         2634        87.8      1995       99.8     639           63.9
  HBcAb            3000                  2000                1000          
  Positive         2094        69.8      2000       100.0    94            9.4
  Negative         906         30.2      0          0.0      906           90.6
  HcvAb            3000                  2000                1000          
  Positive         2957        98.6      1961       98.1     996           99.6
  Negative         43          1.4       39         2.0      4             0.4
  Vaccination      3000                  2000                1000          
  Yes              636         21.2      306        15.3     330           33.0
  No               2364        78.8      1694       84.7     670           67.0
  Surgery          3000                  2000                1000          
  Yes              1541        51.4      966        48.3     575           57.5
  No               1459        48.6      1034       51.7     425           42.5
  Smoking          3000                  2000                1000          
  Yes              490         16.3      363        18.2     127           12.7
  No               2510        83.7      1637       81.9     873           87.3
  Alcohol          3000                  2000                1000          
  Yes              157         5.2       94         4.7      63            6.3
  No               2843        94.8      1906       95.3     937           93.7
  Drug abuse       3000                  2000                1000          
  Yes              198         6.6       179        9.0      19            1.9
  No               2802        93.4      1821       91.1     981           98.1

**Prior specification of HBV sensitivity and specificity: Sample One**

Of the 8,000-person population, 300 were reported cases and controls, while the remaining 7700 were non-reported in the community. Due to the lack of confirmed laboratory and clinical data for correcting classification of cases and controls, based on the simulation framework and knowledge to a low error rate of laboratory tests, 197 were correctly identified as true case patients with 5 false positives while 96 were correctly identified as true non-case patients with 2 false negatives. Assuming a complete case report (E = 0, no underreporting), this corresponds to 99% sensitivity and near perfect specificity. Afterward, by altering the degree of underreporting (E = 5, 50, 500), sensitivity diminished to 97%, 79%, and 29%, respectively ([Table 2](#T2){ref-type="table"}). In addition, the existence of valid data and unnecessary need for expert opinion creates the following set of priors:

$\mathit{SN}_{E = 0}\mathit{\sim beta}\left( 197,2 \right)$, $\mathit{SP}_{E = 0}\mathit{\sim beta}\left( 7796,5 \right)$, $\mathit{SN}_{E = 5}\mathit{\sim beta}\left( 197,7 \right)$, $\mathit{SP}_{E = 5}\mathit{\sim beta}\left( 7791,5 \right)$, $\mathit{SN}_{E = 50}\mathit{\sim beta}\left( 197,52 \right)$, $\mathit{SP}_{E = 50}\mathit{\sim beta}\left( 7746,5 \right)$, $\mathit{SN}_{E = 500}\mathit{\sim beta}\left( 197,502 \right)$, $\mathit{SP}_{E = 500}\mathit{\sim beta}\left( 7296,5 \right)$

**Prior specification of HBV sensitivity and specificity: Sample Two**

As in the first example, Of the 8,000-person population, including 300 reported cases and controls, 181 were correctly identified as true case patients with 7 false positives while 106 were correctly identified as true non-case patients with 6 false negatives. Assuming a complete case report (E = 0, no underreporting), this corresponds to 97% sensitivity and near perfect specificity. Afterward, by varying the degree of underreporting (E = 5, 50, 500), sensitivity declined to 94%, 76%, and 26%, respectively ([Table 3](#T3){ref-type="table"}). In addition, we have the following set of priors: 〖SN〗\_(E=0)\~beta(181,6), \[P〗\_(E=0)\~beta(7806,7), 〖SN〗\_(E=5)\~beta(181,11), 〖SP〗\_(E=5)\~beta(7801,7), 〖SN〗\_(E=50)\~beta(181,56), 〖SP〗\_(E=50)\~beta(7756,7),〖SN〗\_(E=500)\~beta(181,506), 〖SP〗\_(E=500)\~beta(7306,7)

**Prior specification of HBV sensitivity and specificity: Sample Three**

As in previous examples, Of the 8000-person population, including 300 reported cases and controls, 197 were correctly identified as true case patients with 4 false positives while 95 were correctly identified as true non-case patients with 4 false negatives. Assuming a complete case report (E = 0, no underreporting), this corresponds to 98% sensitivity and near perfect specificity. Afterward, by varying the degree of underreporting (E = 5, 50, 500), sensitivity dropped to 96%, 78%, and 28%, respectively ([Table 4](#T4){ref-type="table"}). In addition, we have the following set of priors:

$\mathit{SN}_{E = 0}\mathit{\sim beta}\left( 197,4 \right)$,                    $\mathit{SP}_{E = 0}\mathit{\sim beta}\left( 7795,4 \right)$,                 $\mathit{SN}_{E = 5}\mathit{\sim beta}\left( 197,9 \right)$, $\mathit{SP}_{E = 5}\mathit{\sim beta}\left( 7790,4 \right)$,                 $\mathit{SN}_{E = 50}\mathit{\sim beta}\left( 197,54 \right)$,                 $\mathit{SP}_{E = 50}\mathit{\sim beta}\left( 7745,4 \right)$, $\mathit{SN}_{E = 500}\mathit{\sim beta}\left( 197,504 \right)$, $\mathit{SP}_{E = 500}\mathit{\sim beta}\left( 7295,4 \right)$

**Bayesian Adjustment for correcting bias**

###### 

Specification of prior distribution of HBV sensitivity and specificity as beta distribution by assuming varying degrees of underreporting in the first sample

  Calculation              Specification   Scenario 1: E=0   Scenario 2: E=5   Scenario 3: E=50   Scenario 4: E=500                                               
  ------------------------ --------------- ----------------- ----------------- ------------------ ------------------- ------ --- ------ ------ ---- ------ ------ -----
  Total population         A+B+C+D+E+F     8000                                                   8000                           8000               8000           
  Reported population      A+B+C+D         300                                                    300                            300                300            
  Cases                    A+B             202                                                    202                            202                202            
  non-cases                C+D             98                                                     98                             98                 98             
  Disease Classification                                                                                                                                           
   True positives          A               197                                                    197                            197                197            
   False positives         B               5                                                      5                              5                  5              
  False negatives          C               2                                                      2                              2                  2              
  True negatives           D               96                                                     96                             96                 96             
  Non-reported             E+F             7700                                                   7700                           7700               7700           
  non-cases                F               7700                                                   7695                           7650               7200           
  Underreported cases      E               0                                                      5                              50                 500            
  Sensitivity              A/(A+C+E)       0.99                                                   0.97                           0.79               0.29           
    Beta distribution      (A,C+E)                           197               2                                      197    7          197    52          197    502
  Specificity              (D+F)/(B+D+F)   1.00                                                   1.00                           1.00               1.00           
    Beta distribution      (D+F,B)                           7796              5                                      7791   5          7746   5           7296   5

###### 

Specification of prior distribution of HBV sensitivity and specificity as beta distribution by assuming varying degrees of underreporting in the second sample

  Calculation              Specification   Scenario 1: E=0   Scenario 2: E=5   Scenario 3: E=50   Scenario 4: E=500                                                
  ------------------------ --------------- ----------------- ----------------- ------------------ ------------------- ------ ---- ------ ------ ---- ------ ------ -----
  Total population         A+B+C+D+E+F     8000                                                   8000                            8000               8000          
  Reported population      A+B+C+D         300                                                    300                             300                300           
  Cases                    A+B             188                                                    188                             188                188           
  non-cases                C+D             112                                                    112                             112                112           
  Disease Classification                                                                                                                                           
   True positives          A               181                                                    181                             181                182           
   False positives         B               7                                                      7                               7                  6             
  False negatives          C               6                                                      6                               6                  5             
  True negatives           D               106                                                    106                             106                107           
  Non-reported             E+F             7700                                                   7700                            7700               7700          
  non-cases                F               7700                                                   7695                            7650               7200          
  Underreported cases      E               0                                                      5                               50                 500           
  Sensitivity              A/(A+C+E)       0.97                                                   0.94                            0.76               0.26          
    Beta distribution      (A,C+E)                           181               6                                      181    11          181    56          181    506
  Specificity              (D+F)/(B+D+F)   1.00                                                   1.00                            1.00               1.00          
    Beta distribution      (D+F,B)                           7806              7                                      7801   7           7756   7           7306   7

###### 

Specification of prior distribution of HBV sensitivity and specificity as beta distribution by assuming varying degrees of underreporting in the third sample

  Calculation              Specification   Scenario 1: E=0   Scenario 2: E=5   Scenario 3: E=50   Scenario 4: E=500                                               
  ------------------------ --------------- ----------------- ----------------- ------------------ ------------------- ------ --- ------ ------ ---- ------ ------ -----
  Total population         A+B+C+D+E+F     8000                                                   8000                           8000               8000          
  Reported population      A+B+C+D         300                                                    300                            300                300           
  Cases                    A+B             201                                                    201                            202                202           
  non-cases                C+D             99                                                     99                             98                 98            
  Disease Classification                                                                                                                                          
  True positives           A               197                                                    197                            197                197           
  False positives          B               4                                                      4                              4                  4             
  False negatives          C               4                                                      4                              4                  4             
  True negatives           D               95                                                     95                             95                 95            
  Non-reported             E+F             7700                                                   7700                           7700               7700          
  non-cases                F               7700                                                   7695                           7650               7200          
  Underreported cases      E               0                                                      5                              50                 500           
  Sensitivity              A/(A+C+E)       0.98                                                   0.96                           0.78               0.28          
  Beta distribution        (A,C+E)                           197               4                                      197    9          197    54          197    504
  Specificity              (D+F)/(B+D+F)   1.00                                                   1.00                           1.00               1.00          
  Beta distribution        (D+F,B)                           7795              4                                      7790   4          7745   4           7295   4

###### 

Estimated magnitude of naive and Bayesian-corrected OR by assuming varying degree of underreporting in the first to third samples

  Sample 1                       Analysis and Outcome Measure   OR             95% CrI   95% CrI Ratio
  ------------------------------ ------------------------------ -------------- --------- ---------------
  Sample 2                       Naïve                                                   
  Basis measurement              3.51                           1.88 - 6.71    3.58      
  Bayesian correction                                                                    
  No underreporting              3.75                           2.28 - 6.25    2.74      
   5 True cases not reported     3.94                           2.38 - 6.62    2.78      
   50 True cases not reported    5.15                           3.06 - 8.83    2.88      
   500 True cases not reported   7.24                           4.14 - 13.07   3.16      
  Sample 3                       Naïve                                                   
  Basis measurement              3.37                           1.76 - 6.56    3.73      
  Bayesian correction                                                                    
  No underreporting              3.54                           2.17 - 5.85    2.7       
   5 True cases not reported     3.74                           2.27 - 6.24    2.75      
   50 True cases not reported    5.1                            3.05 - 8.69    2.85      
   500 True cases not reported   7.32                           4.25 - 12.95   3.04      

In the first to third samples, the odds ratios were estimated with raw data. These estimates serve as a basis for comparison, with values of 3.14, 3.51, and 3.37, respectively. After correcting misclassification using the Bayesian approach and the Gibbs sampling algorithm, ideally (i.e. E=0), OR increased to 3.22, 3.75, and 3.54, respectively. As can be seen in [Table 5](#T5){ref-type="table"}, as the degree of underreporting increased, the adjusted OR increased dramatically. In addition, the credible intervals ratios in the corrected state were smaller than in the misclassification state. The autocorrelation functions and time series graphs of β~1~ estimates in the first to third samples for various degrees of underreporting were obtained using 1000 Gibbs iterations and 50% burn-in. In the following, the graphs related to the first sample are presented.

![*Autocorrelation Functions (a) and Time Series(b) Graphs of* *β* ~1~ *Estimates in the First Sample*](GHFBB-12-S136-g001){#F1}

Discussion
==========

The results of the current research indicated that the misclassification rate was mild in the raw data. The odds ratio increased by only a few percent when only 5 persons of rest of the population in the study population were infected with the virus. On the other hand, for 50 and 500 persons of rest of the population, OR estimates increased by about half and more than double, respectively. Another result of our analysis was that despite the varying OR in the samples, the overall results (misclassification rate in raw data, magnitude of increased effect size in scenarios, etc.) were identical according to the pattern of association (association of exposure and response).

In the present study, there are several reasons for the misclassification of vaccination exposure. Indeed, a group of population may be hesitant to receive the vaccine and over time they experience a recall bias. Another group may not be up to date on the vaccination and has received the vaccine less than three times. Another group may have received the vaccine after being infected with hepatitis B virus, in which case the injected vaccine is dysfunctional on the prevention of the virus. Also, HBV infection is diagnosed with serologic markers including HBsAg, which may be associated with a slight error due to inadequate accuracy of laboratory test which leads to the misclassification of patients with Hepatitis B virus and as a result biased the odds ratio in the present research.

Underreporting of HBV and HCV has long been recognized as a challenge. In the study by Robert et al. ([@B23]), the accuracy of state surveillance case registries for recording clinically-confirmed cases of HBV and HCV infections was investigated in few reports. The study indicated that chronic hepatitis B and C went unreported in Pennsylvania Department of Health (PDoH), as compared to patients in the Geisinger Health System of Pennsylvania. In addition, 28% underreporting of HBV and HCV co-infections in the study may lead to biased results about estimation of liver cancer risk ([@B24]--[@B26]). Another study tested the completeness of report of clinically-confirmed cases of chronic HBV and HCV infections in Michigan, which was unreported with 18% for HBV and 35% for HCV. The difference of unreported cases with demographic characteristics in HBV infection was significant only in the year of initial diagnosis ([@B27]).

In a similar study by Goldstein et al. ([@B13]) on the impact of vaccination on pertussis disease that was prone to both exposure and response error, the odds ratio and subsequent vaccine efficacy (VE) were corrected; compared to the misclassification state, such as our analysis, no significant difference was observed. Also, varying the degree of underreporting resulted in a change in sensitivity from 90% to 20% and VE estimate from 57% to 82%, while in our study, OR estimates was greater with varying the degree of underreporting. Perhaps one reason is because of the inherent association between vaccination and hepatitis B virus. In another study, Luta et al. ([@B15]) in the state of misclassification and missing data biases, with a Bayesian method and similar to our study method, compared four models: A model composed of misclassification and missing data biases at the same time, two models each with one of these biases, and a one raw model. They found that despite the different odds ratios across the four models, overall results were similar with respect to the pattern of associations.

To the best of our knowledge, there was no study examining misclassification of HBV infection rate despite public vaccination. Also, most of the studies investigated the effect of misclassification on either exposure or outcome; however, our study simultaneously evaluated the effects of misclassification on both exposure and outcome through the model and compared the resulting effects.

One of the limitations of the current research was lack of data on proper injection of HBV dose for different ages as well as adherence to the cold chain ([@B28]). Secondly, for convenience, we assumed non-differential misclassification. Possibly, by varying the degree of underreporting, cases might have been grouped at an older age causing differential misclassification. Finally, due to the lack of a similar study accurately analyzing our method and subject matter, we were forced to use priors of similar studies. Nevertheless, prior competencies were confirmed during the implementation of the program.

Our study indicated that in retrospective studies of the vaccine and a specific disease/infection associated misclassification error, the actual magnitude of the association has become illusory and the results are underestimated with increasing unreported cases. One solution to this problem is the Bayesian method. In addition, although data from this study were obtained from Taleghani Hospital in Tehran, patients had participated in this study from different cities of Iran. Thus, we can think about generalizing the results to the Iranian society. Finally, the method used in this research can be applied to any arbitrary exposure and response that is prone to misclassification error.
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